Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Data from Systemic Treatment with the Antidiabetic Drug Metformin Selectively Impairs p53-Deficient Tumor Cell Growth

(2023)10.1158/0008-5472.c.6495702Source: DataRank Database

Data from Systemic Treatment with the Antidiabetic Drug Metformin Selectively Impairs p53-Deficient Tumor Cell Growth is a research paper (2023). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:OA: goldTopics (22)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Russell G. Jones ORCID,Ravi K. Amaravadi ORCID,Julian J. Lum ORCID,Ralph J. DeBerardinis ORCID,Fangping Zhao

Live enrichment

PubMed:19022398 OpenAlex:https://openalex.org/W4361243783

goldLicense: cc-by

http://dx.doi.org/10.1158/0008-5472.c.6495702

Fields of Study

Metabolism, Diabetes, and CancerCancer-related Molecular PathwaysPancreatic function and diabetes

Keywords

MetforminAMPKApoptosisAMP-activated protein kinaseActivator (genetics)Cell growthInternal medicineChemistryEndocrinologyGrowth inhibitionMolecular biologyProtein kinase ACancer researchBiologyKinaseDiabetes mellitusMedicineBiochemistryGene

Sustainable Development Goals

SDG 0: Good health and well-being